Ansell Stephen (64 results)

Softcover. Condition: Near Fine. Magazine. Printed wrappers. Octavo. 59pp. Buff wrappers. Bumped and faded spine, near fine. This issue features Roy Campbell, F.L. Lucas, and Jack Lindsay. Additional contributors include N.K. Cruickshank, Doreen Dunlop, Wrey Gardiner, A.H. Heys, Teresa Hooley, Esther Spencer, G.W. Harris, Sonia Bentzon, Freda C. Bond, Denis Turner, Stuart Holroyd, R.V. Blakemore, P.D. Cummins, Justin Richardson, Margaret Stanley-Wrench, Frank Lissauer, Sidonie Schall, Christopher Levenson, Michael Malim, Murrell Simmons, W.H. Hamilton, Laurence H. Williams, Dennis Peck, Valmai Richardson, Mary Banes, Kathleen M. Chapin, F.D. Walker, William Wolff, Alice Alment, S. Thomas Ansell, Peter Fison, Howard Parsons, Robert Greacen, Stephen Graham, John Graddon, Kennedy Williamson, Paul Selver, K.V. Richardson, and E. Royse Pritchard. …

Condition: Good. 1st Edition. Pages intact with minimal writing/highlighting. The binding may be loose and creased. Dust jackets/supplements are not included. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good.

Hardcover. 4to. pp: 98. First edition. Original publisher's black boards with black lettering at spine in original publisher's colour-illustrated dust jacket. Copiously illustrated in black and white and colour. This is number 877 of a limited edition of 900 copies. With DVD included. ISBN: 9780956700407 Fine in near fine dust jacket. Bright, internally and externally clean copy. …

Condition: Sehr gut. Zustand: Sehr gut | Seiten: 452 | Sprache: Englisch | Produktart: Bücher | Many comprehensive text books have been written about the common hematologic malignancies. However, every practicing hematologist/oncologist or primary care physician intermittently encounters patients with uncommon or rare hematologic malignancies. Information concerning these diseases, and particularly regarding their management, is extremely difficult to find. Physicians will commonly spend a substantial period of time searching the medical literature for help or will call a colleague who may have greater expertise in the area.Rare Hematological Malignancies covers malignant hematologic diseases that physicians would see only occasionally, providing accurate, up-to-date information on the disease biology and practical recommendations concerning the disease management.…

Hardback. Condition: Fine. First Edition. Hardback. Dust Jacket. 4to. pp 98. Original publisher's black cloth, lettered blind on spine. Copiously illustrated in colour and black and white throughout. Published on the occasion of the exhibition 'Fallen Visionary' held at The Cuming Museum, Southwark 13 September to 14 November 2010. Limited edition of 900 standard copies, this being no. 353. Including a DVD, titled' The Bones Go Last' (written by Richard Millington and Thomas Oldham). ISBN: 0956700403 Fine in fine dust jacket.…

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: New.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Condition: new.

Condition: New.

HRD. Condition: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Condition: New. New Book. Shipped from UK. Established seller since 2000.

Condition: new.

Condition: New.

Condition: New.

Condition: As New. Unread book in perfect condition.

Condition: As New. Unread book in perfect condition.

Condition: New. In English.

Condition: New. In English.

Hardcover. Condition: new. Hardcover. Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biologyFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanismsCovers FDA-approved drugs and their indications, as well as drugs currently in developmentProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacyIncludes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Hardcover. Condition: new. Hardcover. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into information that can be directly applied to patients hence the subtitle, From Concept to Practice. To aid in readers comprehension, the first page of each chapter contains a box entitled Take Home Points. This short text will highlight the major unique points about the information contained within the chapter. Some of the key topics addressed in the work are as follows: Biological basis of the lymphoid malignancies: fundamental principles of lymphomagenesis and molecular classification of lymphoid malignanciesTargeting programmed cell death: principles for understanding the many types of cell death and promising combinations of drugs targeting apoptosisTargeting the PI3K pathway: understanding the intricacies of this complex biology and precisely how targeted drugs can be leveraged therapeuticallyTargeting the cancer epigenome: pharmacologic features of drugs targeting the epigenome and future prospects for targeting various aspects of epigenetic controlTargeting the tumour proteome: understanding the mechanisms of protein degradation in cancer including both older drugs like proteasome inhibitors, and newer PROTAC based approaches Written primarily for scientists and physicians in both the public and private sectors, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice is a comprehensive reference work for those interested in the growing area of Precision Cancer Therapies. Seamlessly integrating the basic and applied science, this volume will be an indispensable reference for those interested in translating the most important advances in science to innovative novel treatments for patients. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Hardback. Condition: New. Volume 2. Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biologyFocuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanismsCovers FDA-approved drugs and their indications, as well as drugs currently in developmentProvides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacyIncludes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.…

Hardback. Condition: New. Volume 1. Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into information that can be directly applied to patients - hence the subtitle, From Concept to Practice. To aid in readers' comprehension, the first page of each chapter contains a box entitled 'Take Home Points'. This short text will highlight the major unique points about the information contained within the chapter. Some of the key topics addressed in the work are as follows: Biological basis of the lymphoid malignancies: fundamental principles of lymphomagenesis and molecular classification of lymphoid malignanciesTargeting programmed cell death: principles for understanding the many types of cell death and promising combinations of drugs targeting apoptosisTargeting the PI3K pathway: understanding the intricacies of this complex biology and precisely how targeted drugs can be leveraged therapeuticallyTargeting the cancer epigenome: pharmacologic features of drugs targeting the epigenome and future prospects for targeting various aspects of epigenetic controlTargeting the tumour proteome: understanding the mechanisms of protein degradation in cancer including both older drugs like proteasome inhibitors, and newer PROTAC based approaches Written primarily for scientists and physicians in both the public and private sectors, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice is a comprehensive reference work for those interested in the growing area of Precision Cancer Therapies. Seamlessly integrating the basic and applied science, this volume will be an indispensable reference for those interested in translating the most important advances in science to innovative novel treatments for patients.…

Condition: New.

Condition: New. 2023. 1st Edition. Hardcover. . . . . .

Condition: New. 2024. Volume 2. hardcover. . . . . .

Condition: Used. pp. 448.